

# **EXHIBIT 6**

1 UNITED STATES DISTRICT COURT  
 2 FOR THE NORTHERN DISTRICT OF OHIO  
 3 EASTERN DIVISION

4 IN RE: NATIONAL )  
 5 PRESCRIPTION ) MDL No. 2804  
 6 OPIATE LITIGATION )  
 7 \_\_\_\_\_ ) Case No.  
 8 ) 1:17-MD-2804  
 9 )  
 10 THIS DOCUMENT RELATES ) Hon. Dan A.  
 11 TO ALL CASES ) Polster  
 12 )

13 THURSDAY, JULY 19, 2018

14 HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER  
 15 CONFIDENTIALITY REVIEW

16 - - -

17 Videotaped deposition of Gary L.  
 18 Boggs, held at the offices of The Cochran  
 19 Firm, D.C., 1100 New York Avenue, NW, Suite  
 20 340, Washington, DC, commencing at 9:05 a.m.,  
 21 on the above date, before Carrie A. Campbell,  
 22 Registered Diplomat Reporter and Certified  
 23 Realtime Reporter.

24 - - -

25 GOLKOW LITIGATION SERVICES  
 877.370.3377 ph | 917.591.5672 fax  
 deps@golkow.com

1 Q. Yes, sir.

2 A. Not that I'm aware of, no.

3 Q. That discretion is left to  
4 the -- is left to McKesson or was left to  
5 McKesson, true?

6 MR. STANNER: Objection to the  
7 form.

8 QUESTIONS BY MR. HAWAL:

9 Q. By the DEA?

10 A. I believe that's the case, yes.

11 Q. Have you ever seen any document  
12 whereby McKesson communicated to the DEA that  
13 it was incapable of identifying suspicious  
14 orders or stopping their shipment?

15 A. Not that I recall, no.

16 Q. You were also identified as a  
17 person most knowledgeable at McKesson about  
18 controlled substance quotas, but we were told  
19 that McKesson has no documents relating to  
20 controlled substance quotas and does not set  
21 quotas.

22 Is that familiar to you, sir?

23 MR. STANNER: Objection --

24 THE WITNESS: It's familiar to  
25 me, yes.

1 MR. STANNER: -- to the form.

2 QUESTIONS BY MR. HAWAL:

3 Q. So is there any role -- does  
4 McKesson play any role in setting quotas or  
5 contributing to the establishment of quotas  
6 for controlled substances?

7 MR. STANNER: Objection to the  
8 form.

9 THE WITNESS: The Drug  
10 Enforcement Administration sets the  
11 quotas.

12 QUESTIONS BY MR. HAWAL:

13 Q. All right. And McKesson and  
14 other distributors do not play a role in  
15 that?

16 A. The only role that we would  
17 play is the ARCOS reporting, the data that we  
18 report via ARCOS, which is considered as part  
19 of the DEA determination when setting the  
20 quotas. That would be the only role that we  
21 would play.

22 MR. HAWAL: All right. I don't  
23 have any further questions. We are  
24 going to reserve our right to reopen  
25 this deposition once McKesson complies

Highly Confidential - Subject to Further Confidentiality Review

ACKNOWLEDGMENT OF DEPONENT

I, GARY BOGGS, do  
hereby certify that I have read the foregoing  
pages and that the same is a correct  
transcription of the answers given by me to  
the questions therein propounded, except for  
the corrections or changes in form or  
substance, if any, noted in the attached  
Errata Sheet.

Gary L. Boggs  
Gary L. Boggs

8/22/2018  
DATE

Subscribed and sworn to before me this  
22ND day of August, 20 18.

My commission expires: 2-1-2022

Notary Public

MARSHA SHAMOUN VENET

**Marsha Shamoun Venet**  
**NOTARY PUBLIC - STATE OF MICHIGAN**  
**COUNTY OF OAKLAND**  
**MY COMMISSION EXPIRES FEB 01, 2022**  
**ACTING IN THE COUNTY OF Wayne**



## ERRATA SHEET

Case Name: In re: National Prescription Opiate Litigation  
No. 1:17-MD-2804


Deposition Date: July 19, 2018

Deponent: Gary Boggs

- |    |                                 |
|----|---------------------------------|
| 1. | To clarify the record.          |
| 2. | To conform to the facts.        |
| 3. | To correct transcription error. |

Pg.	Line	Now Reads	Should Read	Reason
16	23	pharma	Pharma	2
17	16	2016	2006	3
29	23	2016	2006	3
30	1	I was not. At the Drug	I was not at the Drug	3
77	19	Once, I don't	I don't	1
77	21	raising a question	raising in the question	3
90	22	fill mills	pill mills	3

Date: 8/22/2018

  
Gary Boggs